Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 16.4.2024Fresenius Kabi Deutschland GmbH (FRK-1)4527ETyenne 20 mg/ml koncentrát na infúzny roztok (con inf 1x10 ml/200 mg (liek.inj.skl.))16.4.2024U
 16.4.2024Fresenius Kabi Deutschland GmbH (FRK-1)4532ETyenne 162 mg injekčný roztok v naplnenej injekčnej striekačke (sol iru 4x0,9 ml/162 mg (striek.inj.napl.skl.))16.4.2024U
 16.4.2024Fresenius Kabi Deutschland GmbH (FRK-1)4525ETyenne 20 mg/ml koncentrát na infúzny roztok (con inf 1x4 ml/80 mg (liek.inj.skl.))16.4.2024U
 16.4.2024Mylan Pharmaceuticals Limited (MLB-IE-1)9262BRasagiline Mylan 1 mg tablety (tbl 28x1 mg (blis.PVC/PVDC/Al))16.4.2024O
 16.4.2024Mylan Ireland Limited (MNY)5331CAripiprazol Mylan 10 mg orodispergovateľné tablety (tbl oro 28x10 mg (blis.PA/Al/PVC/Al/papier/PET-perfor.))16.4.2024O
 16.4.2024VUAB Pharma a.s. (VUA-1)3563EHydrocortison VUAB 100 mg (plv ino 1x4 ml/100 mg (liek.inj.skl.+uzáver Al s plast. viečkom))15.4.2024U
 16.4.2024Instituto Grifols, S.A. (GFO)45084Flebogamma DIF 50 mg/ml infúzny roztok (sol inf 1x400 ml/20 g (liek.skl.))1.5.2024Z
 16.4.2024Instituto Grifols, S.A. (GFO)45083Flebogamma DIF 50 mg/ml infúzny roztok (sol inf 1x200 ml/10 g (liek.skl.))1.5.2024Z
 16.4.2024Instituto Grifols, S.A. (GFO)45082Flebogamma DIF 50 mg/ml infúzny roztok (sol inf 1x100 ml/5 g (liek.skl.))1.5.2024Z
 15.4.2024Bayer AG (BYE-4)77019Ultravist 370 mg I/ml (sol inj 10x100 ml (fľ.skl.))15.4.2024O
 15.4.2024Instituto Grifols, S.A. (GFO)45082Flebogamma DIF 50 mg/ml infúzny roztok (sol inf 1x100 ml/5 g (liek.skl.))15.4.2024O
 15.4.2024Instituto Grifols, S.A. (GFO)45083Flebogamma DIF 50 mg/ml infúzny roztok (sol inf 1x200 ml/10 g (liek.skl.))15.4.2024O
 15.4.2024Instituto Grifols, S.A. (GFO)45084Flebogamma DIF 50 mg/ml infúzny roztok (sol inf 1x400 ml/20 g (liek.skl.))15.4.2024O
 15.4.2024Teva B.V. (TEV-NL-4)0466EAtorvastatín/Ezetimib Teva 20 mg/10 mg (tbl flm 90x20 mg/10 mg (blis.OPA/Al/PVC/Al))12.4.2024O
 15.4.2024Zentiva, k.s. (ZNT-1)4238EDiozen Forte (tbl flm 90x1000 mg (blis.PVC/Al))24.4.2024U

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)